Clinical Trial: Clinical Evaluation of 177Lu-FAP-VG11 Injection in Patients With Fibroblast Activation Protein -Positive Advanced Solid Tumours

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07808177) titled 'Clinical Evaluation of 177Lu-FAP-VG11 Injection in Patients With Fibroblast Activation Protein -Positive Advanced Solid Tumours' on Aug. 18.

Brief Summary: This is an exploratory clinical study evaluating the safety, tolerability and biodistribution characteristics of 177Lu-FAP-VG11 injection in patients with FAP-positive advanced solid tumours.

Study Start Date: June 17

Study Type: INTERVENTIONAL

Condition: Fibroblast Activation Protein (FAP)-Positive Advanced Solid Tumours

Intervention: DRUG: 177Lu-FAP-VG11

Patients will receive 177Lu-FAP-VG11 administration at an interval of 6 weeks between each dose.

Recruitment Status: ...